Veronica Schmitz Pereira
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ferreira, Cassio Porto
NCT03947437: Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

Not yet recruiting
1b/2a
142
RoW
LEP-F1 + GLA-SE, LepVax, Placebo
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz), Oswaldo Cruz Institute
Leprosy
03/24
04/25
NCT06627257: Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy

Not yet recruiting
1
54
RoW
LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose, LepVax, LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose, Placebo Comparator: Placebo, Sterile normal saline for injection.
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz), Oswaldo Cruz Institute
Leprosy
03/26
08/26
Pereira, Veronica
PATRICIA, NCT02448420 / 2014-005006-38: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Completed
2
73
Europe
Palbociclib, Ibrance, Trastuzumab, Herceptin, Endocrine therapy, ET, Chemotherapy, CT, Antibody-Drug Conjugates, Trastuzumab emtansine (TDM-1)
SOLTI Breast Cancer Research Group
Metastatic Breast Cancer
09/23
11/23
NCT03947437: Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

Not yet recruiting
1b/2a
142
RoW
LEP-F1 + GLA-SE, LepVax, Placebo
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz), Oswaldo Cruz Institute
Leprosy
03/24
04/25

Download Options